Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$25.93M
Enterprise ValueAU$23.17M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding810,175,300
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformAtomo’s integrated hardware platform is a durable competitive asset: supplying a single-device solution to test manufacturers creates product stickiness and OEM dependency. As partners adopt the Atomo form factor, recurring device volumes from programs and manufacturers can underpin steady B2B revenue over months.
Low LeverageMinimal debt reduces solvency and interest burden risk, giving management optionality to fund operations, R&D, or absorb revenue volatility without immediate refinancing. For a loss-making medical-device firm, low leverage materially lowers near-term bankruptcy risk and preserves strategic flexibility.
Gross Margin LevelA near-50% gross margin indicates favorable unit economics on device manufacturing and potential pricing power with OEM buyers. If sustained, strong gross margins provide a pathway to operational leverage and eventual profitability when fixed costs are absorbed by higher volumes.
Bears Say
Revenue DeclineA sustained revenue decline reduces scale and undermines the unit economics of a device business that relies on volume to cover fixed manufacturing and R&D costs. Continued top-line contraction limits cash generation, weakens partner confidence, and makes hitting profitable scale more difficult over the next several months.
Deep Negative ProfitabilityVery large negative margins signal the company is losing significant cash on core operations, reflecting low volumes, pricing pressure, or high fixed costs. Without structural cost reduction or revenue scaling, these deficits will persist and materially impair returns and reinvestment capacity.
Weak Cash GenerationNegative OCF and sharply deteriorating FCF growth indicate the business is consuming cash rather than generating it. Even with low debt this creates a durable liquidity risk: continued negative cash flow will require external funding or dilution, constraining investment in production, sales, or product development.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$25.93M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Apr 23, 2026 which is in 17 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Atomo Diagnostics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 810,175,300 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Atomo Diagnostics Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.895%.
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Technical Analysis
Options Prices
Currently, No data available
---